Radiation before transplant: a new way to vaccinate against lung cancer?
NCT ID NCT04782752
First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time
Summary
Researchers are testing whether giving targeted radiation to lung tumors before a lung transplant can create an immune response that helps the body fight cancer. The trial enrolls adults with end-stage lung disease and hard-to-treat lung cancer who need a transplant. The goal is to find the highest radiation dose that is safe and to see if patients can be listed for transplant one week after radiation ends.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- non-ablative oligofractionated radiation therapy
- What this could lead to
- If it works, radiation before transplant could train the immune system to fight lung cancer and lower the chance of the cancer coming back after surgery.
- What could go wrong
- This is a small, early-stage safety trial, so researchers do not yet know if the radiation dose is safe or if it triggers a useful immune response. The immune effect may not appear, and radiation carries risks of lung damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2021
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 * Patients with end-stage lung disease and suspected stage I primary lung cancer based on CT and PET scan not accessible to curative treatment, including surgery and ablative SBRT. * Patients with multifocal pulmonary malignancy, including multifocal lung adenocarcinoma, not accessible to curative treatment, including surgery and ablative SBRT. * Patients with isolated metastases in one or both lungs after complete resection of the primary tumor in the absence of other sites of metastatic disease, not accessible to curative treatment, including surgery and ablative SBRT. * Meet eligibility criteria for lung transplantation with the exception of the underlying malignancy. * Subjects must be able to understand the potential risks and benefits of the study and must be able to read and provide written, informed consent for the study. Exclusion Criteria: * Age \< 18 * Mediastinal nodes metastasis demonstrated on EBUS-TBNA * Distant metastasis demonstrated on PET scan or brain imaging. * Failure to provide informed consent * Previous thoracic radiation resulting in significant mediastinal or chest wall overlap precluding re-irradiation * Any other medical condition that, in the opinion of the multidisciplinary team, may interfere with the subject's participation or compliance with the treatment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Multifocal lung adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Toronto General Hospital, University Health Network
RECRUITINGToronto, Ontario, M5G 2C4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.